NEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NeoGenomics Inc (NEO) is not a strong buy at the moment for a long-term beginner investor. While the company has positive developments in research and collaborations, its financial performance shows declining profitability, and technical indicators do not suggest a strong upward momentum. Additionally, there are no strong proprietary trading signals or significant trading trends to support a buy decision.
The MACD is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 51.683, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 8.031, with resistance at 8.604 and support at 7.458. Overall, the technical indicators suggest a neutral outlook.
NeoGenomics is presenting significant research at the AACR Annual Meeting, highlighting advancements in oncology data solutions and collaborations with biopharma partners. These developments could enhance its reputation and future growth potential.
The stock has a 70% probability of declining in the short term (-1.08% in the next day, -3.66% in the next week, -7.68% in the next month). Financial performance shows a drop in net income (-35.52% YoY), EPS (-33.33% YoY), and gross margin (-2.43% YoY), indicating challenges in profitability.
In Q4 2025, revenue increased by 10.56% YoY to $190.17M, showing growth in sales. However, net income dropped by 35.52% YoY to -$9.88M, EPS fell by 33.33% YoY to -0.08, and gross margin declined by 2.43% YoY to 43.83%. This indicates revenue growth but worsening profitability.
Piper Sandler recently raised the price target from $12 to $13 and maintained an Overweight rating, showing optimism from analysts. However, the current price of $8.18 is significantly below the target, suggesting room for growth but also potential risks.
